News und Analysen
Humana’s 2020 Bold Goal Progress Report Details Improved Mental and Physical Health Among its Population
Humana Inc. (NYSE: HUM) today unveiled its “2020 Bold Goal Progress Report,” which details the company’s progress in its ambitious population health strategy launched in 2015 to improve the health
Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn
Upjohn Inc. (“Newco”), a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”) (NYSE: PFE), Upjohn Finance B.V. (“Finco”), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. (“Mylan”) (Nasdaq
Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale
Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that
Waters Corporation Announces CEO Succession Plan
Waters Corporation (NYSE:WAT) today announced that the Company’s Board of Directors and Christopher O’Connell have mutually agreed that Mr. O’Connell will step down as President, Chief Executive
Nanobiotix Receives Feedback From US FDA to Advance Phase III Head and Neck Cancer Study Design and CMC Development Plan for NDA
Regulatory News:
“With our recent Fast Track designation for NBTXR3 in this patient population, acceptance of the design of our pivotal phase III trial and agreement on our CMC plan, Nanobiotix
Recordati Rare Diseases: Phase-III-Studie LINC-4 zu Isturisa® (Osilodrostat) erreicht primären Endpunkt bei Morbus Cushing
Recordati Rare Diseases meldet heute positive Ergebnisse der großen Phase-III-Studie LINC-4 zur Prüfung von Isturisa® (Osilodrostat) zur Behandlung von Patienten mit Morbus Cushing, die für eine
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand viewing and
Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing’s Disease
Recordati Rare Diseases today announces positive results from the large Phase III LINC-4 study of Isturisa® (osilodrostat) for the treatment of patients with Cushing’s disease for whom pituitary
Sensorion Announces Initiation of Coverage by US Investment Bank Chardan with a “Buy” Recommendation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
NanoString Announces New Products to Advance COVID-19 Disease Research
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the availability of new solutions to study the immune
Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies
Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S. District Court for the Northern District of California issued a preliminary injunction order against several BGI companies, including MGI
Lantheus Stockholders Approve Share Issuance For Merger with Progenics
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 28, 2020. The purpose
Lantheus Holdings to Present at the BMO 2020 Prescriptions for Success Virtual Healthcare Conference
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of
Humana Announces Monthly Stipend to Reduce Costs for Dental Providers During Pandemic
Today, Humana Inc. (NYSE: HUM) announced new actions it is taking to support participating dental providers – to help them afford the increased costs of doing business during the coronavirus
IMV Announces Leading Independent Proxy Advisory Firms Recommend Shareholders Vote FOR All Resolutions at Upcoming Annual and Special Meeting
IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), have recommended
AstraZeneca: Kurs-Irrsinn nach Impfstoff-News
Papiere des britischen Pharmakonzerns AstraZeneca (WKN: 886455) verteuern sich heute Morgen um zeitweise +30% auf 120 Euro. Börsenlaien lassen sich von einem am Wochenende vermeldeten Impfstoff-Deal
VALBIOTIS wurde ausgewählt, auf den 80. wissenschaftlichen Sitzungen der American Diabetes Association die klinischen Phase-II-Ergebnisse zu TOTUM-63 bei Prädiabetes vorzustellen
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Thursday, June 18, 2020 at 11:30 a.m. EDT. The
LivaNova Announces Pricing of Private Offering of $250 Million of 3.00% Cash Exchangeable Senior Notes Due 2025
LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senior notes due 2025 to be issued by its wholly owned U.S
Bayer: Aktie weiterhin ein Schnäppchen!
Nachdem es an der Börse wochenlang quasi nur nach oben ging, sahen wir gestern endlich mal wieder einen Korrekturtag. Aufgrund des Sell Offs geriet letztlich auch die Aktie von Bayer (WKN: BAY001)
VALBIOTIS Selected at the 80th Scientific Sessions of the American Diabetes Association to Present Phase II Clinical Results of TOTUM-63 in Prediabetes
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces
Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
Quidel Announces Jack Schuler Will Retire From Quidel’s Board of Directors
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Jack W. Schuler
FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved NYVEPRIA™ (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegfilgrastim).1 NYVEPRIA